Cyrano Therapeutics has developed a unique, proprietary intranasal formulation to restore function in patients with a chronic loss of taste and smell.  This is a condition affecting more than 40 million people in the US and Europe and millions more across the world, having a significant impact on safety, quality of life and well-being.  Currently no marketed pharmaceutical therapy exists and aside from the Cyrano product, none are in the pipeline.
 
The Cyrano formulation (CYR-064) has been tested with success in a 92 patient pilot study and the Company is currently enrolling patients in a Phase 2 placebo-controlled double-blind randomized trial at 14 sites in the United States with data readout expected in Q1'25.

Additional information can be found on our website www.cyranotherapeutics.com





 


Remiges Ventures

Lumira Ventures

Cyrano Therapeutics

OptiNose is a pharmaceutical company that develops and commercializes products for patients with ear, nose, and throat (ENT) disorders, including chronic rhinosinusitis.

OptiNose

Intersect ENT is a company specializing in the development and commercialization of therapies for chronic rhinosinusitis and other ear, nose, and throat conditions.

Intersect ENT

Sanofi is a multinational pharmaceutical company that has a portfolio of products for various therapeutic areas, including treatments for chronic rhinosinusitis.

Sanofi

Cyrano Therapeutics is a biotechnology company focused on the development of therapeutics for diseases of the nose and sinuses. The company's lead product candidate is aimed at addressing chronic rhinosinusitis, a condition that affects millions of people worldwide.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 12, 2024 1:57 PM	b68fd2f7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	0434abbe
crunchbase profile	general
li profile	general	May 12, 2024 1:57 PM	1f70c474
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 12, 2024 1:57 PM	9291c1ea
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CYRANOTHERAPEUTICS

Cyrano Therapeutics